Concordia University has enhanced its sustainable biomanufacturing capabilities through a $5 million investment from the Canada Foundation for Innovation (CFI), which includes 40% funding from the CFI and matching contributions from Quebec’s Ministry of Higher Education. This strategic investment aims to upgrade the Genome Foundry and bioprocessing facilities, positioning Concordia as a leader in synthetic biology and bioprocessing in Canada.
The upgraded facilities will enable the university to develop biobased products comprehensively, from the design of microbial and mammalian cells to the testing and refinement of new medicines and chemicals that are traditionally derived from non-sustainable sources. According to Steve Shih, co-director of the Centre for Applied Synthetic Biology, this advancement will accelerate research and facilitate the transition of promising technologies into practical applications across critical sectors such as health, agriculture, and clean energy.
By providing access to these advanced biomanufacturing facilities, Concordia aims to bolster national research capacity and support small- to medium-sized enterprises, academic partners, and government collaborators. This access not only expedites the journey from discovery to market but also fosters high-skilled job creation. Furthermore, the environmental implications are significant, as these technologies aim to replace fossil fuel-derived chemicals and reduce waste, thereby contributing to a more sustainable future.
Open the full market picture for your next decision →
